company background image
CUV logo

Clinuvel Pharmaceuticals ASX:CUV Voorraadrapport

Laatste prijs

AU$13.16

Marktkapitalisatie

AU$669.3m

7D

-2.7%

1Y

-22.0%

Bijgewerkt

21 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Clinuvel Pharmaceuticals Limited

ASX:CUV Voorraadrapport

Marktkapitalisatie: AU$669.3m

CUV Overzicht aandelen

Clinuvel Pharmaceuticals Limited, een biofarmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van behandelingen voor patiënten met genetische, metabole, systemische en levensbedreigende aandoeningen in Australië, Europa, de Verenigde Staten, Zwitserland en internationaal. Meer informatie

Clinuvel Pharmaceuticals Limited Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Clinuvel Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoersAU$13.16
52 Week HoogtepuntAU$18.20
52 Week LaagAU$12.96
Bèta0.85
11 maand verandering-4.64%
3 maanden verandering-1.57%
1 Jaar Verandering-21.99%
33 jaar verandering-56.92%
5 jaar verandering-54.07%
Verandering sinds IPO1,216.00%

Recent nieuws en updates

Recent updates

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jun 27
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

May 09
Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Mar 24
Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18
An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20
Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30
Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27
Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14
Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03
This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23
A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23
Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10
With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06
Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27
Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20
What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01
Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14
Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28
We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21
What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Rendement voor aandeelhouders

CUVAU BiotechsAU Markt
7D-2.7%-3.6%1.5%
1Y-22.0%10.0%17.2%

Rendement versus industrie: CUV presteerde slechter dan de Australian Biotechs -sector, die het afgelopen jaar een rendement van 10 % opleverde.

Rendement versus markt: CUV presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 17.2 % opleverde.

Prijsvolatiliteit

Is CUV's price volatile compared to industry and market?
CUV volatility
CUV Average Weekly Movement4.7%
Biotechs Industry Average Movement9.7%
Market Average Movement8.6%
10% most volatile stocks in AU Market17.3%
10% least volatile stocks in AU Market3.4%

Stabiele aandelenkoers: CUV heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van CUV is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
1999n/aPhilippe Wolgenwww.clinuvel.com

Clinuvel Pharmaceuticals Limited, een biofarmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van behandelingen voor patiënten met genetische, metabole, systemische en levensbedreigende aandoeningen in Australië, Europa, de Verenigde Staten, Zwitserland en internationaal. De belangrijkste kandidaat is SCENESSE, een systemisch fotoprotectief geneesmiddel voor de preventie van fototoxiciteit bij volwassen patiënten met erytropoëtische protoporfyrie (EPP). De pijplijnproducten van het bedrijf omvatten CUV9900 en Parvysmelanotide (VLRX001), beide analogen voor alfa-melanocyten stimulerend hormoon; en PRÉNUMBRA, een vloeibare injecteerbare formulering van afamelanotide.

Clinuvel Pharmaceuticals Limited Samenvatting

Hoe verhouden de winst en inkomsten van Clinuvel Pharmaceuticals zich tot de beurswaarde?
CUV fundamentele statistieken
MarktkapitalisatieAU$669.29m
Inkomsten(TTM)AU$35.64m
Inkomsten(TTM)AU$88.18m

18.4x

Koers/Winstverhouding

7.5x

P/S-verhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CUV resultatenrekening (TTM)
InkomstenAU$88.18m
Kosten van inkomstenAU$7.73m
BrutowinstAU$80.45m
Overige uitgavenAU$44.81m
InkomstenAU$35.64m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)0.71
Brutomarge91.23%
Nettowinstmarge40.41%
Schuld/Eigen Vermogen Verhouding0%

Hoe presteerde CUV op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.4%

Huidig dividendrendement

7%

Uitbetalingsratio